RxDoctor Payments Data

Sonya Cothran-Pate

Nurse Practitioner · Piedmont, SCNPI 1447335633

Payments from drug & device makers

$386in general payments, 2019–2025

Across 19 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$165
  • Abbott$44
  • Merck$43
  • Lilly USA, LLC$32
  • Eisai Inc.$29
  • Philips North America LLC$26
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$386100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$386 in reported general payments places this provider in the 65th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$13,080
Medicare patients
48
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$68,402
FarxigaDapagliflozin Propanediol39$57,941
JanuviaSitagliptin Phosphate20$22,601
JardianceEmpagliflozin21$18,336
EliquisApixaban16$13,398
Incruse ElliptaUmeclidinium Bromide12$4,378
Breo ElliptaFluticasone/Vilanterol11$4,141
Albuterol Sulfate HfaAlbuterol Sulfate120$3,765
SymbicortBudesonide/Formoterol Fumarate11$3,220
Novolog FlexpenInsulin Aspart17$2,706
Nano 2nd Gen Pen NeedlePen Needle, Diabetic27$1,736
Omeprazole153$1,491
Atorvastatin Calcium141$1,184
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,126
Levothyroxine Sodium155$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$165$68,40265 claims
MerckJanuvia$43$22,60120 claims
Boehringer IngelheimJardiance$18$18,33621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Piedmont

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →